Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000694998 | SCV000823472 | likely benign | Hereditary spastic paraplegia 30; Neuropathy, hereditary sensory, type 2C; Intellectual disability, autosomal dominant 9 | 2023-11-21 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000997712 | SCV001153387 | uncertain significance | not provided | 2018-12-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000997712 | SCV001788820 | uncertain significance | not provided | 2023-02-13 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Genome Diagnostics Laboratory, |
RCV001849060 | SCV002104824 | uncertain significance | Hereditary spastic paraplegia | 2017-10-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002406593 | SCV002715137 | uncertain significance | Inborn genetic diseases | 2022-02-02 | criteria provided, single submitter | clinical testing | The p.T616M variant (also known as c.1847C>T), located in coding exon 20 of the KIF1A gene, results from a C to T substitution at nucleotide position 1847. The threonine at codon 616 is replaced by methionine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |